Sponsors (7)
The bill trades stronger, class-wide Schedule I controls that can reduce availability of potent nitazene opioids and give law enforcement clearer authority for increased barriers to legitimate research, the risk of criminalizing low-level exposures and small actors, potential underground market shifts that complicate harm reduction, and added taxpayer costs.
People at risk of overdose — including low-income and urban communities — and emergency responders are likely to face fewer deaths and overdoses because class-wide Schedule I control reduces the availability of highly potent nitazene-related opioids in illicit markets.
Law enforcement and prosecutors gain clearer, immediate authority to investigate and prosecute possession, distribution, and trafficking of nitazene-related compounds under Schedule I rules, streamlining investigations and prosecutions.
Federal and state agencies (DEA/DOJ and related regulators) face reduced regulatory uncertainty about how to enforce controls on nitazene-related substances.
Scientists and patients: Making nitazene-related compounds Schedule I creates additional DEA registration and compliance hurdles that will delay or deter legitimate research and potential therapeutic development.
Low-income individuals, people who use drugs, small businesses, manufacturers, and distributors risk criminalization or enforcement for possession or trace contamination because permanent class-wide scheduling and coverage of isomers/salts could penalize inadvertent presence.
Public health and harm-reduction: Tighter scheduling may push production and distribution further underground, complicating overdose surveillance, harm-reduction outreach, and accurate monitoring of emerging threats.
Based on analysis of 3 sections of legislative text.
Permanently adds all 2-benzylbenzimidazole opioids (nitazenes) to Schedule I with a structural definition and list of covered substances.
Permanently places an entire chemical class of synthetic opioids known as 2-benzylbenzimidazole opioids (commonly called nitazenes and related compounds) into Schedule I of the Controlled Substances Act, and provides a structural definition plus a list of named substances covered. Any nitazene or related compound that had been temporarily scheduled is deemed permanently Schedule I as of enactment, and the law clarifies that research with these substances still requires proper registration and regulatory authorization. The change aims to close a gap used by illicit drug makers who create new analogs to evade scheduling, streamline criminal enforcement, and reduce overdose risk by treating the whole structural class as illegal except for authorized, registered research uses.
Official title: Amend the Controlled Substances Act to permanently schedule the class of 2-benzylbenzimidazole-opioids known as nitazenes, and for other purposes.
Introduced October 30, 2025 by David Harold McCormick · Last progress October 30, 2025